Mainz BioMed NV (MYNZ) Actualités

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN

December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in...

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Announces Stock Split

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]